Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
28 nov. 2017 06h40 HE
|
Auris Medical AG
HEALOS trial did not meet primary efficacy endpoint in overall study population Clinically and statistically significant improvement in subpopulation of patients with profound acute hearing...
Auris Medical News Release
21 nov. 2017 08h00 HE
|
Auris Medical AG
Auris Medical to Report Third Quarter 2017 Financial Results and Provide Business Update on Tuesday, November 28, 2017 Zug, Switzerland, November 21, 2017 - Auris Medical Holding AG (NASDAQ:...
Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC
11 oct. 2017 06h45 HE
|
Auris Medical AG
Zug, Switzerland, October 11, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Announces Transfer to Nasdaq Capital Market
28 sept. 2017 08h30 HE
|
Auris Medical AG
Zug, Switzerland, September 28, 2017 - Auris Medical Holding AG (the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Provides Board of Directors Update
26 sept. 2017 08h30 HE
|
Auris Medical AG
Zug, Switzerland, September 26, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
22 sept. 2017 08h00 HE
|
Auris Medical AG
Trial now includes more than 730 patients under previously announced amended protocol Top-line results from TACTT3 expected in first quarter 2018 Zug, Switzerland, September 22, 2017 - Auris...
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
20 sept. 2017 08h00 HE
|
Auris Medical AG
ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting
05 sept. 2017 08h00 HE
|
Auris Medical AG
ZUG, Switzerland, Sept. 5, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...
Auris Medical Announces Receipt of Nasdaq Notice
24 août 2017 16h05 HE
|
Auris Medical AG
Zug, Switzerland, August 24, 2017 - Auris Medical Holding AG ("the Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...
Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
10 août 2017 06h30 HE
|
Auris Medical AG
Phase 3 results from AM-111 HEALOS trial expected in fourth quarter 2017 Phase 3 results from Keyzilen® TACTT3 trial expected in first quarter 2018 Conference call set for 8 am EDT (2 pm CEST)...